- Patient population In the dose escalation cohorts: Patients with pathologically confirmed B cell malignancy (i.e. DLBCL, CLL, small lymphocytic lymphoma [SLL], follicular lymphoma [FL], mantle cell lymphoma (MCL), Morbus Waldenström [MW], Marginal zone lymphoma [MZL], with at least 1, but not more than 3 prior lines of therapy.